Kathryn J. Collier, Director at Regulus Therapeutics Inc. (RGLS), bought 7,100 shares at $1.41 ($10K) on 2018-11-16, disclosed to the SEC on 2018-11-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.